Department of Hospital Medicine, Ochsner Medical Center, New Orleans, LA, USA.
Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, LA, USA ; Department of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA.
Ther Clin Risk Manag. 2014 Jun 24;10:485-92. doi: 10.2147/TCRM.S36983. eCollection 2014.
Hypertriglyceridemia is a highly prevalent lipid abnormality and it is associated with atherosclerosis, with a growing body of evidence linking elevated triglycerides (TGs) with cardiovascular disease. The current major omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) combination, lowers serum TGs while often increasing levels of low-density lipoprotein cholesterol. Icosapent ethyl is an omega-3 polyunsaturated fatty acid with a 96% pure ethyl ester of EPA that has been recently approved for lowering TG levels in patients with very high TGs (≥500 mg/dL), and it does so without significantly affecting serum low-density lipoprotein cholesterol. The potential benefits of omega-3 fatty acid therapy for dyslipidemias will be discussed, including the potential pros and cons of EPA alone versus the more common and readily available EPA/DHA combination therapy.
高甘油三酯血症是一种常见的脂质异常，与动脉粥样硬化有关，越来越多的证据表明，甘油三酯（TGs）升高与心血管疾病有关。目前主要的欧米伽-3 多不饱和脂肪酸，二十碳五烯酸（EPA）/二十二碳六烯酸（DHA）联合用药，可降低血清 TG 水平，同时常升高低密度脂蛋白胆固醇水平。二十碳五烯酸乙酯是一种欧米伽-3 多不饱和脂肪酸，其 96%为 EPA 的纯乙酯，最近被批准用于降低极高甘油三酯（≥500mg/dL）患者的 TG 水平，且不会显著影响血清低密度脂蛋白胆固醇。将讨论欧米伽-3 脂肪酸治疗血脂异常的潜在益处，包括单独使用 EPA 的潜在利弊与更为常见且易于获得的 EPA/DHA 联合治疗。
